Rituximab in the management of acute lymphoblastic leukemia

References

• Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11–30.
   PubMed Web of Science ®Google Scholar
• National Cancer Institute. SEER stat fact sheet: acute lymphocytic leukemia. [ cited 2014]. Available from: http://seer.cancer.gov/statfacts/html/alyl.html
   Google Scholar
• Pui C-H, Mullighan CG, Evans WE, et al. Pediatric acute lymphoblastic leukemia: where are we going and how do we get there? Blood. 2012;120(6):1165–1174.
   PubMed Web of Science ®Google Scholar
• Dombret H, Cluzeau T, Huguet F, et al. Pediatric-like therapy for adults with ALL. Curr Hematol Malig Rep. 2014;9:158–164.
   PubMed Web of Science ®Google Scholar
• Gökbuget N, Hoelzer D. Treatment of adult acute lymphoblastic leukemia. Hematol Am Soc Hematol Educ Program. 2006;133–141.
   PubMedGoogle Scholar
• Gaynon PS, Trigg ME, Heerema NA, et al. Children’s Cancer Group trials in childhood acute lymphoblastic leukemia: 1983–1995. Leukemia. 2000;14:2223–2233.
   PubMed Web of Science ®Google Scholar
• Sive JI, Buck G, Fielding A, et al. Outcomes in older adults with acute lymphoblastic leukaemia (ALL): results from the international MRC UKALL XII/ECOG2993 trial. Br J Haematol. 2012;157(4):463–471.
   PubMed Web of Science ®Google Scholar
• Fielding AK, Rowe JM, Buck G, et al. UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia. Blood. 2014;123(6):843–850.
   PubMed Web of Science ®Google Scholar
• Béné MC, Nebe T, Bettelheim P, et al. Immunophenotyping of acute leukemia and lymphoproliferative disorders: a consensus proposal of the European LeukemiaNet Work Package 10. Leukemia. 2011;25:567–574.
   PubMed Web of Science ®Google Scholar
• Maury S, Huguet F, Leguay T, et al. Adverse prognostic significance of CD20 expression in adults with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia. Haematologica. 2010;95:324–328.
   PubMed Web of Science ®Google Scholar
• Thomas DA, O’Brien S, Jorgensen JL, et al. Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia. Blood. 2009 Jun 18;113(25):6330–6337.
   PubMed Web of Science ®Google Scholar
• Thomas DA, O’Brien S, Faderl S, et al. Chemoimmunotherapy with a modified hyper- CVAD and Rituximab regimen improves out come in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. J Clin Oncol. 2010;28(24):3880–3889.
   PubMed Web of Science ®Google Scholar
• Thomas DA, Faderl S, O’Brien S, et al. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer. 2006;106(7):1569–1580.
   PubMed Web of Science ®Google Scholar
• Hoelzer D, Walewski J, Döhner H, et al. Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial. German Multicenter Study Group for adult acute lymphoblastic leukemia. Blood. 2014 Dec 18;124(26):3870–3879.
   PubMed Web of Science ®Google Scholar
• Rizzieri DA, Johnson JL, Byrd JC, et al.; Alliance for Clinical Trials in Oncology (ACTION). Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: Cancer and Leukemia Group B study 10 002. Br J Haematol. 2014;165(1):102–111.
   PubMed Web of Science ®Google Scholar
• Leget GA, Czuczman MS. Use of rituximab, the new FDA-approved antibody. Curr Opin Oncol. 1998 Nov;10(6):548–551.
   PubMedGoogle Scholar
• Grillo-Lopez AJ, White CA, Varns C, et al. Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma. Semin Oncol. 1999;26(5 Suppl 14):66–73.
   PubMed Web of Science ®Google Scholar
• Tedder TF, Engel P. CD20: a regulator of cell-cycle progression of B lymphocytes. Immunol Today. 1994;15:450–454.
   PubMedGoogle Scholar
• Müller C, Murawski N, Wiesen MH, et al. The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL. Blood. 2012 Apr 5;119(14):3276–3284.
   PubMed Web of Science ®Google Scholar
• Rituxan (Rituximab) package insert. San Francisco (CA): Genentech; 2012 - Highlights of prescribing information (https://www.gene.com/download/pdf/rituxan_prescribing.pdf)
   Google Scholar
• Davies A, Merli F, Mihaljević B, et al. Efficacy and safety of subcutaneousrituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial. Lancet Haematol. 2017 Jun;4(6):e272–e282.
   PubMed Web of Science ®Google Scholar
• Coiffier B. Pharmacokinetics, efficacy and safety of the rituximab biosimilar CT-P10. Expert Rev Clin Pharmacol. 2017 Sep;10(9):923–933.
   PubMed Web of Science ®Google Scholar
• Lamanna WC, Heller K, Schneider D, et al. The in-use stability of the rituximab biosimilar Rixathon®/Riximyo® upon preparation for intravenous infusion. J Oncol Pharm Pract. 2017 Jan 1:1078155217731506. [Epub ahead of print]. DOI:10.1177/1078155217731506
   Google Scholar
• Kim WS, Buske C, Ogura M, et al. Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 compared with rituximab in patients with previously untreated advanced-stage follicular lymphoma: a randomised, double-blind, parallel-group, non-inferiority phase 3 trial. Lancet Haematol. 2017 Aug;4(8):e362–e373.
   PubMed Web of Science ®Google Scholar
• Bene MC, Castoldi G, Knapp W, et al. Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia. 1995;9:1783–1786.
   PubMed Web of Science ®Google Scholar
• Piccaluga PP, Arpinati M, Candoni A, et al. Surface antigens analysis reveals significant expression of candidate targets for immunotherapy in adult acute lymphoid leukemia. Leuk Lymphoma. 2011;52(2):325–327.
   PubMed Web of Science ®Google Scholar
• Raponi S, De Propris MS, Intoppa S, et al. Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases. Leuk Lymphoma. 2011;52(6):1098–1107.
   PubMed Web of Science ®Google Scholar
• Dworzak MN, Schumich A, Printz D, et al. CD20 up-regulation in pediatric B-cell precursor acute lymphoblastic leukemia during induction treatment: setting the stage for anti-CD20 directed immunotherapy. Blood. 2008;112:3982–3988.
   PubMed Web of Science ®Google Scholar
• McLaughlin P, Grillo-López AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998;16:2825–2833.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Thomas D, Wayne AS, et al. Monoclonal antibody-based therapies: a new dawn in the treatment of acute lymphoblastic leukemia. J Clin Oncol. 2012;30:3876–3883.
   PubMed Web of Science ®Google Scholar
• Wang S-Y, Weiner G. Complement and cellular cytotoxicity in antibody therapy of cancer. Expert Opin Biol Ther. 2008;8:759–768.
   PubMed Web of Science ®Google Scholar
• Wang S-Y, Raci la E, Taylor RP, et al. NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement. Blood. 2008;111:1456–1463.
   PubMed Web of Science ®Google Scholar
• Wang SY, Veeramani S, Racila E, et al. Depletion of the C3 component of complement enhances the ability of rituximab-coated target cells to activate human NK cells and improves the efficacy of monoclonal antibody therapy in an in vivo model. Blood. 2009;114:5322–5330.
   PubMed Web of Science ®Google Scholar
• Griffin TC, Weitzman S, Weinstein H, et al. A study of rituximab and ifosfamide, carboplatin, and etoposide chemotherapy in children with recurrent/refractory B-cell (CD20) non-Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia: a report from the Children’s Oncology Group. Pediatr Blood Cancer. 2009;52:177–181.
   PubMed Web of Science ®Google Scholar
• Intermesoli T, Rambaldi A, Rossi G, et al. High cure rates in Burkitt lymphoma and leukemia: a Northern Italy Leukemia Group study of the German short intensive rituximab-chemotherapy program. Haematologica. 2013 Nov;98(11):1718–1725.
   PubMed Web of Science ®Google Scholar
• Ribera J-M, García O, Grande C, et al. Dose-intensive chemotherapy including rituximab in Burkitt’s leukemia or lymphoma regardless of human immunodeficiency virus infection status: final results of a phase 2 study (Burkimab). Cancer. 2013 May 1;119(9):1660–1668. Epub 2013 Jan 29.
   PubMed Web of Science ®Google Scholar
• Ribrag V, Koscielny S, Bosq J, et al. Rituximab and dose-dense chemotherapy for adults with Burkitt’s lymphoma: a randomised, controlled, open-label, phase 3 trial. Lancet. 2016 Jun 11;387(10036):2402–2411.
   PubMed Web of Science ®Google Scholar
• Maury S, Chevret S, Thomas X, et al.; for GRAALL. Rituximab in B-lineage adult acute lymphoblastic leukemia. N Engl J Med. 2016 Sep 15;375(11):1044–1053.
   PubMed Web of Science ®Google Scholar
• Huguet F, Leguay T, Raffoux E, et al. Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study. J Clin Oncol. 2009;27:911–918.
   PubMed Web of Science ®Google Scholar
• Jabbour E, O’Brien S, Ravandi F, et al. Monoclonal antibodies in acute lymphoblastic leukemia. Blood. 2015 Jun 25;125(26):4010–4016.
   PubMed Web of Science ®Google Scholar
• Herter S, Herting F, Mundigl O, et al. Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models. Mol Cancer Ther. 2013;12(10):2031–2042.
   PubMed Web of Science ®Google Scholar
• Kern DJ, James BR, Blackwell S, et al. GA101 induces NK-cell activation and antibody-dependent cellular cytotoxicity more effectively than rituximab when complement is present. Leuk Lymphoma. 2013 Nov;54(11):2500–2505.
   PubMed Web of Science ®Google Scholar
• Tobinai K, Klein C, Oya N, et al. A review of obinutuzumab (GA101), a novel type II anti-CD20 monoclonal antibody, for the treatment of patients with B-cell malignancies. Adv Ther. 2017;34(2):324–356.
   PubMed Web of Science ®Google Scholar
• Jabbour E, Kantarjian H, Thomas D, et al. Phase II study of the hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with CD-20 positive acute lymphoblastic leukemia [abstract]. Blood. 2014;124:5277.
   Google Scholar
• Wei G, Wang J, Huang H, et al. Novel immunotherapies for adult patients with B-lineage acute lymphoblastic leukemia. J Hematol Oncol. 2017 Aug 18;10(1):150. Review.
   PubMed Web of Science ®Google Scholar
• Mori J, Tsuda K, Tanimoto T. Inotuzumab ozogamicin for acute lymphoblastic leukemia. N Engl J Med. 2016 Nov 24;375(21):2100.
   PubMed Web of Science ®Google Scholar
• Paul S, Rausch CR, Kantarjian H, et al. Treatment of adult acute lymphoblastic leukemia with inotuzumab ozogamicin. Future Oncol. 2017 Aug 4;13:2233–2242.
   PubMed Web of Science ®Google Scholar